502887-71-0
中文名稱
MMP-9-IN-1
英文名稱
MMP-9-IN-1
CAS
502887-71-0
分子式
C16H17F2N3O3S
分子量
369.39
MOL 文件
502887-71-0.mol
更新日期
2026/05/25 13:08:19
502887-71-0 結(jié)構(gòu)式
基本信息
中文別名
化合物MMP-9-IN-1N-(4-(二氟甲氧基)苯基)-2-((6-氧代-4-丙基-1,6-二氫嘧啶-2-基)硫代)乙酰胺
英文別名
OUN87710MMP-9-IN-1
Acetamide, N-[4-(difluoromethoxy)phenyl]-2-[(1,6-dihydro-6-oxo-4-propyl-2-pyrimidinyl)thio]-
物理化學(xué)性質(zhì)
密度1.37±0.1 g/cm3(Predicted)
儲(chǔ)存條件Inert atmosphere,2-8°C
溶解度DMSO: 125 mg/mL (338.40 mM)
酸度系數(shù)(pKa)7.80±0.50(Predicted)
形態(tài)Solid
顏色White to off-white
MMP-9-IN-1價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-135232 | MMP-9-IN-1 MMP-9-IN-1 | 502887-71-0 | 5mg | 1250元 |
| 2026/06/05 | HY-135232 | MMP-9-IN-1 MMP-9-IN-1 | 502887-71-0 | 10mM * 1mLin DMSO | 1375元 |
| 2026/06/05 | HY-135232 | MMP-9-IN-1 MMP-9-IN-1 | 502887-71-0 | 10mg | 2000元 |
常見問題列表
生物活性
MMP-9-IN-1 (OUN87710)是一種 matrix metalloproteinase-9 (MMP-9) 的特異性抑制劑。MMP-9-IN-1 可選擇性地靶向MMP-9的血紅素(PEX)域，Kd值為2.1 μM。靶點(diǎn)
| Target | Value |
|
MMP-9
(Cell-free assay) | 2.1 μM(Kd) |
體外研究
MMP-9-IN-1 (compound 2; 100 μM; 14 hours) does not cause notable cytotoxicity.
MMP-9-IN-1 (compound 2; 10 μM) significantly inhibits cell proliferation of HT-1080 and MDA-MB-435 cells.
Cell Cytotoxicity Assay
| Cell Line: | COS-1 monkey epithelial cell lines |
| Concentration: | 100 μM |
| Incubation Time: | 24 hours |
| Result: | Treatment did not cause notable cytotoxicity. |
Cell Proliferation Assay
| Cell Line: | HT-1080 and MDA-MB-435 cancer cells expressing endogenous MMP-9 |
| Concentration: | 10 μM |
| Incubation Time: | 9 days |
| Result: | Significant inhibition of cell proliferation. |
體內(nèi)研究
MMP-9-IN-1 (compound 2; 20 mg/kg; intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks) results in a profound delay in tumor growth in NCR-Nu mice bearing MDA-MB-435/GFP tumor.
MMP-9-IN-1 inhibits cancer cell metastasis in vivo.
| Animal Model: | 4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks, |
| Result: |
Resulted in a profound delay in tumor growth.
Inhibited cancer cell metastasis. |